Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study
Value in Health · 2024-12 · 27 (12) · 1641-1647
DOI: 10.1016/j.jval.2024.07.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2024-12. Verfasst von Alexa C Klimchak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global HEOR, RWE, and Analytics, Sarepta Therapeutics, Inc, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Quality-Adjusted Life Years, Cost-Benefit Analysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sarepta Therapeutics, Inc., Sarepta Therapeutics.
Abstract (Originalsprache)
OBJECTIVES: Quality-adjusted life years (QALYs) have been challenged as a measure of benefit for people with disabilities, particularly for those in low-utility health states or with irreversible disability. This study examined the impact of a QALY-based assessment on the price for a hypothetical treatment for Duchenne muscular dystrophy (DMD), a progressive, genetic neuromuscular disease. METHODS: A previously published, 5-state model, which analyzed treatments for early ambulatory (EA) DMD patients, was replicated, validated, and adapted to include early nonambulatory (ENA) DMD patients. The model was used to assess a QALY-based threshold price (maximum cost-effective price) for a hypothetical treatment for 13-year-old ENA and 5-year-old EA patients (initial health states with lower and higher utility, respectively). All inputs were replicated including willingness-to-pay thresholds of $50 000 to $200 000/QALY. RESULTS: In contrast to EA patients, ENA patients had a 98% modeled decline in QALY-based threshold price at a willingness-to-pay of $150 000/QALY or higher, despite equal treatment benefit (delayed progression/death). At $100 000/QALY or lower, net nontreatment costs exceeded health benefits, implying any treatment for ENA patients would not be considered cost-effective, even at $0 price, including an indefinite pause in disease progression. CONCLUSIONS: For certain severe, disabling conditions, traditional approaches are likely to conclude that treatments are not cost-effective at any price once a patient progresses to a disabled health state with low utility value. These findings elucidate theoretical/ethical concerns regarding potential discriminatory properties of traditional QALY assessments for people with disabilities, particularly those who have lost ambulation or have other physical limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global HEOR, RWE, and Analytics, Sarepta Therapeutics, Inc, Cambridge, MA, USA.
- School of Pharmacy, University of Maryland, Baltimore, MD, USA.
- College of Pharmacy, University of Utah, Salt Lake City, UT, USA. Electronic address: Dan.Malone@utah.edu.
Förderung
- Sarepta Therapeutics, Inc.
- Sarepta Therapeutics
Zitieren
APA
Klimchak, A. C., Sedita, L. E., Perfetto, E. M., Gooch, K. L., & Malone, D. C. (2024). Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study. Value in Health, 27(12), 1641-1647. https://doi.org/10.1016/j.jval.2024.07.008
Vancouver
Klimchak AC, Sedita LE, Perfetto EM, Gooch KL, Malone DC. Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study. Value in Health. 2024;27(12):1641-1647. doi:10.1016/j.jval.2024.07.008
BibTeX
@article{Klimchak2024,
author = {Klimchak, Alexa C and Sedita, Lauren E and Perfetto, Eleanor M and Gooch, Katherine L and Malone, Daniel C},
title = {Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study},
journal = {Value in Health},
year = {2024},
volume = {27},
number = {12},
pages = {1641--1647},
doi = {10.1016/j.jval.2024.07.008}
}
EUVIMED